Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $-63M | $-66M | $-75M | -30.7% | -51.4% | -18.7% |
| 2024 | $138M | $-77M | $-81M | $-60M | -33.6% | -12.3% | 172.3% |
| 2023 | $158M | $-24M | $-30M | $-21M | -10.7% | -23.3% | -417.9% |
| 2022 | $206M | $14M | $9M | $24M | 3.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 67.22 |
| Operating Revenue | 67.22 |
| Operating Expense | 143.48 |
| Research And Development | 112.21 |
| Selling General And Administration | 46.08 |
| Total Expenses | 143.48 |
| Operating Income | -76.26 |
| Total Operating Income As Reported | -76.26 |
| EBITDA | -62.75 |
| Normalized EBITDA | -63.13 |
| EBIT | -65.77 |
| Interest Income | 10.10 |
| Interest Expense | 0.01 |
| Net Interest Income | 10.10 |
| Other Income Expense | 0.38 |
| Interest Income Non Operating | 10.10 |
| Interest Expense Non Operating | 0.01 |
| Net Non Operating Interest Income Expense | 10.10 |
| Pretax Income | -65.78 |
| Tax Provision | 0 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -65.78 |
| Net Income From Continuing And Discontinued Operation | -65.78 |
| Net Income From Continuing Operation Net Minority Interest | -65.78 |
| Net Income | -65.78 |
| Net Income Common Stockholders | -65.78 |
| Net Income Including Noncontrolling Interests | -65.78 |
| Normalized Income | -66.17 |
| Diluted NI Availto Com Stockholders | -65.78 |
| Basic Average Shares | 27.39 |
| Diluted Average Shares | 27.39 |
| Reconciled Depreciation | 3.02 |
| Total Unusual Items | 0.38 |
| Total Unusual Items Excluding Goodwill | 0.38 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Gain On Sale Of Security | 0.38 |
| General And Administrative Expense | 46.08 |
| Other Gand A | 46.08 |
| Total Other Finance Cost | - |
| Other Operating Expenses | -14.81 |
| Earnings From Equity Interest | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.this co. | ARCT | $229M | -3.47 | 1.07 | -30.7% | -0.36 |
| Treace Medical Concepts, Inc. | TMCI | $239M | -4.06 | 2.74 | -67.6% | -6.98 |
| LifeMD, Inc. | LFMD | $236M | 16.41 | 10.17 | 62.0% | -135.17 |
| Spok Holdings, Inc. | SPOK | $228M | 14.38 | 1.56 | 10.8% | 8.90 |
| LENZ Therapeutics, Inc. | LENZ |
| 2021 | - | - | - | - | - | - | - |
| $226M |
| - |
| 0.79 |
| -28.9% |
| - |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M | -1.83 | 1.12 | -61.1% | -1.49 |
| Peer Median | - | -2.39 | 1.19 | -24.7% | -1.89 | |